D.E. Shaw & Co’s NextCure NXTC Stock Holding History

D.E. Shaw & Co’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,155	Closed	-$19.5K	–	4735
2022 Q4	$19.5K	Buy	+1,155	New	+$26.6K	﹤0.01%	4529
2021 Q4	–	Sell	-1,065	Closed	-$86K	–	5616
2021 Q3	$86K	Sell	1,065 -2,018	-65%	-$177K	﹤0.01%	4742
2021 Q2	$297K	Sell	3,083 -613	-17%	-$62.7K	﹤0.01%	4282
2021 Q1	$444K	Buy	3,696 +250	+7%	+$36.2K	﹤0.01%	3558
2020 Q4	$451K	Buy	+3,446	New	+$445K	﹤0.01%	3435
2020 Q3	–	Sell	-6,514	Closed	-$1.68M	–	4055
2020 Q2	$1.68M	Buy	+6,514	New	+$2.48M	﹤0.01%	2547
2020 Q1	–	Sell	-2,022	Closed	-$1.37M	–	4147
2019 Q4	$1.37M	Buy	+2,022	New	+$1.01M	﹤0.01%	2766

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co's NXTC Position: Q1 2023 in Review

D.E. Shaw & Co sold out of NextCure (NXTC) in Q1 2023, closing a stake of 1,155 shares — an estimated $19.5K sold.

D.E. Shaw & Co first reported a position in NXTC in Q4 2019 and held it in 7 quarters. The position peaked at $1.68M in Q2 2020. 43 funds tracked by Wall St. Rank hold NXTC as of Q1 2023.

D.E. Shaw & Co reported no remaining NextCure position as of Q1 2023 after selling out during the quarter.
D.E. Shaw & Co sold 1,155 NextCure shares in Q1 2023, an estimated $19.5K.
D.E. Shaw & Co first reported a position in NextCure in Q4 2019 and held it in 7 quarters.
D.E. Shaw & Co's NextCure position peaked at $1.68M in Q2 2020.
43 funds tracked by Wall St. Rank held NextCure as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.